The UK Government's Vaccine Taskforce: strategy for protecting the UK and the world

@article{Bingham2021TheUG,
  title={The UK Government's Vaccine Taskforce: strategy for protecting the UK and the world},
  author={Kate Bingham},
  journal={Lancet (London, England)},
  year={2021},
  volume={397},
  pages={68 - 70}
}
  • K. Bingham
  • Published 27 October 2020
  • Engineering
  • Lancet (London, England)
Hopes, hesitancy and the risky business of vaccine development
Recent policy conversations about vaccination programmes primarily target the problem of vaccine hesitancy and the lack of public participation at the level required for community immunity, or herd
Which vaccination strategy against COVID-19?
TLDR
The vaccine is effective in containing the deaths caused by the virus, particularly when multiple doses have been administered, and the stability of the vaccine pipeline plays a critical role in determining the effectiveness of the vaccination campaign.
What Matters for Depression and Anxiety During the COVID-19 Quarantine?: Results of an Online Cross-Sectional Survey in Seoul, South Korea
TLDR
The need to develop precautionary measures to prevent depression and anxiety among people undergoing COVID-19 quarantine is highlighted, in particular, individuals with depression prior to quarantine should be carefully monitored during the quarantine.
Vaccine nationalism will persist: global public goods need effective engagement of global citizens
Covid-19 presents a unique opportunity to transform democratic engagement in the governance of global public goods. In this paper, I describe a global public goods framework and how it relates to
References
  • Power, Policy and the Pandemic
  • 2022
Institutional Responsibility is Prior to Personal Responsibility in a Pandemic
Taking these sentiments together, it was hard to avoid the conclusion that the government took responsibility only for doing everything right. Such an admission of responsibility, accommodating no
A continuation of a timeline of ivermectin-related events in the COVID-19 pandemic
TLDR
There was a noticeable centralization of power, with the pandemic response largely directed by a few public-private partnerships working on commercializable technologies.
Vaccination against COVID-19 and society’s return to normality in England: a modelling study of impacts of different types of naturally acquired and vaccine-induced immunity
TLDR
Under optimistic scenarios, mass immunisation using efficacious vaccines may enable society safely to return to normality, however, under plausible scenarios with low vaccine efficacy and short durability of immunity, COVID-19 could continue to cause recurrent waves of severe morbidity and mortality despite frequent vaccinations.
Explaining divergent National Responses to Covid-19: An Enhanced State Capacity Framework
ABSTRACT We develop a state capacity framework to account for different national responses to Covid-19. Our starting point is the influential idea that neoliberalism has a major role to play in state
...
...

References

SHOWING 1-7 OF 7 REFERENCES
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
TLDR
The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults support the selection of BNT162b2 for advancement to a pivotal phase 2–3 safety and efficacy evaluation.
WHO Coronavirus Disease (COVID-19) Dashboard
  • C. E.
  • Psychology, Medicine
  • 2020
Globally, as of 10:47am CEST, 28 May 2020, there have been 5,556,679 confirmed cases of COVID-19, including 351,866 deaths, reported to WHO
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
TLDR
The most frequent local adverse event (AE) was injection site pain and the most frequent solicited AEs were fatigue, headache and myalgia, indicative of a Th1-skewed phenotype in both cohorts.
2 Centers for Disease Control and Prevention. Provisional death counts for coronavirus disease 2019 (COVID19): daily updates of totals by week and state
    JCVI: updated interim advice on priority groups for COVID19 vaccination
      Coronavirus vaccine studies volunteers dashboard
      • National Health Service Digital